[News] Biomarkers for subtypes of pancreatic ductal adenocarcinoma

23:08 EST 9 Nov 2017 | The Lancet

Patients with pancreatic ductal adenocarcinoma have a poor prognosis, and those with advanced disease do not survive longer than 12 months, even after cancer treatment. One reason therapy might fail to improve survival is that pancreatic ductal adenocarcinoma could comprise several subtypes of disease, each requiring different treatments. Now, findings from a study by Alexander Muckenhuber (Technical University Munich, Munich, Germany) and colleagues suggest that subtypes identified by immunohistochemistry-based expression of cytokeratin 81 (KRT81) and hepatocyte nuclear factor 1A (HNF1A) have different survival outcomes and responses to chemotherapy.

Original Article: [News] Biomarkers for subtypes of pancreatic ductal adenocarcinoma


More From BioPortfolio on "[News] Biomarkers for subtypes of pancreatic ductal adenocarcinoma"

Quick Search


Relevant Topics

Pancreatic Cancer
The pancreas secretes a number of important hormones into the digestive tract and the blood stream. Cancers are most commonly exocrine than endocrine (neuroendocrine) tumors. Functional tumors secrete hormones; Insulinoma, Gastrinoma, Somatostatinoma, VI...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...